In addition, Cmpd-43, a PRZ-3 inhibitor which interferes with PRL trimerization and possesses more specificity to PRZs, demonstrates anticancer activity against melanomas in vitro and in the xenograft model [205], and recently-developed monoclonal anti-PRL-3 antibody also exhibited anticancer activity in vitro and in vivo [206]; however, the effectiveness of these PRL-3 inhibitors in GBM treatment is not confirmed yet. The gene discussed is PTP4A3; the disease is melanoma.